Pharming Group’s (PHAR) “Buy” Rating Reiterated at HC Wainwright

Posted by Brian Himes on Sep 25th, 2026

HC Wainwright reissued their buy rating on shares of Pharming Group (NASDAQ:PHAR – Free Report) in a report issued on Tuesday morning,Benzinga reports. They currently have a $37.00 target price on the stock.

Several other research analysts have also commented on PHAR. Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a research note on Thursday, July 30th. Canaccord Genuity Group lifted their target price on shares of Pharming Group from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Pharming Group in a research note on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $38.67.

View Our Latest Stock Report on Pharming Group

Pharming Group Trading Down 3.1%

Shares of PHAR stock opened at $10.44 on Tuesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01. Pharming Group has a 52-week low of $9.62 and a 52-week high of $21.34. The company has a market capitalization of $738.94 million, a PE ratio of 87.00 and a beta of 0.01. The business’s fifty day moving average is $11.50 and its 200 day moving average is $13.50.

Pharming Group (NASDAQ:PHAR – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. On average, equities research analysts anticipate that Pharming Group will post 0.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP acquired a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group accounts for about 6.0% of MAC Alpha Capital Management LP’s investment portfolio, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned approximately 3.03% of Pharming Group at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

(Get Free Report)

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.